Company intelligence / Profile preview

Pfenex Inc.

San Diego, California, United States
Ownership
Private
Development stage
Other
01

Overview

Pfenex was acquired by Ligand Pharmaceuticals in 2020. Prior to acquisition, they had several products in development and some approved products including a biosimilar to Forteo (teriparatide) for osteoporosis treatment. Their platform technology has been used in multiple approved vaccines and therapeutics.

Therapeutic areas
EndocrinologyInfectious Diseases
Modalities
Proteinsantibody derivativesenzymespeptidescytokinesantigensvaccinesnanobodies
Industry
Biotech
02

Partnerships

Serum Institute of IndiaAlvogenMerck & Co.Jazz Pharmaceuticals

Beyond the preview

Go deeper on Pfenex Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pfenex Inc..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call